We are live on ! Find out more

Inovio Pharmaceuticals

INO

Market cap $172M

1.66 USD

-0.23

12.17%

At close Updated Nov 3, 4:00 PM EST

Pre-market

After hours

1.65

-0.01

0.6%

1 day

-12.17%

5 days

78.53%

1 month

44.35%

3 months

138.23%

6 months

45.61%

Year to date

-1.78%

1 year

-33.6%

5 years

-98.15%

10 years

-97.69%

About: Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Employees: 112

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 31.8%

Neutral 68.2%

Negative 0%

Schaeffers Research

4 Biotech Stocks Seeing Unusual Options Volume Today

Four pharmaceutical and biotech stocks are seeing unusual options activity today, with Inovio Pharmaceuticals Inc (NASDAQ:INO), Aquestive Therapeutics Inc (NASDAQ:AQST), X4 Pharmaceuticals Inc (NASDAQ:XFOR), and Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) all drawing elevated volume.

4 Biotech Stocks Seeing Unusual Options Volume Today

INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026

PLYMOUTH MEETING, Pa., Nov. 2, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its third quarter 2026 financial results will be released after the market close on November 10, 2026.

INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026

INOVIO to Participate in Upcoming Scientific Conferences

PLYMOUTH MEETING, Pa., Nov. 2, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conferences: Soft Bones Third International Scientific Meeting on Hypophosphatasia (New York) Presentation: Rare Disease Protein Replacement Therapeutics: The Transformational Potential of Next-Gen DNA Medicine Date: Sunday, November 8 World Federation of Hemophilia - New Technology & Gene Therapy (NTGT) Workshop (Montreal) Presentation: INO-D001 for Hemophilia A Date: Thursday, November 12 Abstracts and presentations will be added to our events page if available.

INOVIO to Participate in Upcoming Scientific Conferences

Inovio Pharmaceuticals, Inc. (INO) Discusses FDA Accelerated Approval and Commercial Launch of VOCERYQ for RRP Transcript

Inovio Pharmaceuticals, Inc. (INO) Discusses FDA Accelerated Approval and Commercial Launch of VOCERYQ for RRP Transcript

Inovio Pharmaceuticals, Inc. (INO) Discusses FDA Accelerated Approval and Commercial Launch of VOCERYQ for RRP Transcript

Inovio Stock Soars Following FDA Approval for Rare Respiratory Disease Immunotherapy

Inovio Pharmaceuticals Inc. (NASDAQ:INO) stock is surging on Monday with a session volume of 8.969 million, compared to an average volume of 4.604 million, according to Benzinga Pro data.

Inovio Stock Soars Following FDA Approval for Rare Respiratory Disease Immunotherapy

Inovio Wins FDA Approval for VOCERYQ, Its First Commercial Product

Inovio Pharmaceuticals NASDAQ: INO said the U.S. Food and Drug Administration granted accelerated approval to VOCERYQ, formerly known as INO-3107, as a nonsurgical treatment intended to reduce the frequency of surgeries in adults with recurrent respiratory papillomatosis, or RRP.

Inovio Wins FDA Approval for VOCERYQ, Its First Commercial Product

Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket

Shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) rose sharply in pre-market trading after the company disclosed that the FDA has granted accelerated approval for Voceryq for the treatment of adults with recurrent respiratory papillomatosis.

Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket

Apple, Marriott International and 3 Stocks to Watch Heading Into Monday

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:

Apple, Marriott International and 3 Stocks to Watch Heading Into Monday

INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)

INOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and debilitating disease that often requires surgery VOCERYQ™ is a plasmid DNA-based immunotherapy that targets the root cause of RRP: HPV-6 and HPV-11 INOVIO expects to make VOCERYQ available to order and ship in approximately 60 days, with full commercial launch in the first quarter of 2027 VOCERYQ represents the first U.S. FDA approved DNA medicine, validating INOVIO's novel platform technology INOVIO will host a conference call Monday, November 2, 2026 at 8:00 AM ET PLYMOUTH MEETING, Pa., Oct. 30, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, to reduce the frequency of surgery in adults with RRP.

INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

PLYMOUTH MEETING, Pa., Oct. 20, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it secured a judgment in its favor, in the amount of $80,416,101, on all claims it filed against defendants VGXI, Inc. ("VGXI") and GeneOne Life Science, Inc. ("GeneOne") in the case captioned INOVIO Pharmaceuticals, Inc. v.

INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science

See News Rankings

Price charts implemented using Lightweight Charts™